Emerging evidence indicates JAK inhibitors could be a valuable alternative for managing checkpoint inhibitor–induced immune toxicities, especially in difficult-to-treat cases.
The post Targeted Therapies for Checkpoint Inhibitor Toxicities first appeared on Physician’s Weekly.
